TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)
Brief Summary: The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.


Options:
A: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: AMR101 (ethyl icosapentate) - 2 g/day; Type: EXPERIMENTAL; Interventions: Drug: AMR101 (ethyl icosapentate) - 2 g/day | Arm Label: AMR101 (ethyl icosapentate) - 4 g/day; Type: EXPERIMENTAL; Interventions: Drug: AMR101 (ethyl icosapentate) - 4 g/day | Intervention Type: DRUG; Name: AMR101 (ethyl icosapentate) - 4 g/day; Assigned to Arm(s): AMR101 (ethyl icosapentate) - 4 g/day | Intervention Type: DRUG; Name: AMR101 (ethyl icosapentate) - 2 g/day; Assigned to Arm(s): AMR101 (ethyl icosapentate) - 2 g/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)
Brief Summary: The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.


Options:
A: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)
Brief Summary: The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.


Options:
A: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
B: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo
C: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
D: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)
Brief Summary: The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.


Options:
A: Arm Label: EPANOVA; Type: EXPERIMENTAL; Interventions: Drug: Epanova® (omega-3 carboxylic acids) | Arm Label: Corn oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: corn oil control | Intervention Type: DRUG; Name: Epanova® (omega-3 carboxylic acids); Assigned to Arm(s): EPANOVA | Intervention Type: DRUG; Name: corn oil control; Assigned to Arm(s): Corn oil
B: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Eicosapentaenoic acid ethyl ester | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester; Assigned to Arm(s): A
D: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)
Brief Summary: The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.


Options:
A: Arm Label: Dietary Intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Intervention; Assigned to Arm(s): Dietary Intervention
B: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
D: Arm Label: Omega-3 supplements; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplements; Assigned to Arm(s): Omega-3 supplements | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Safety and Efficacy of MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Combination With Low-Dose CsA, Tac or Sir in Comparison to Current Standard Immunosuppression (MMF, CsA and Corticosteroids) in Renal Tx
Brief Summary: To determine the renal function, as expressed by the glomerular filtration rate at 12 months, in renal transplant recipients receiving mycophenolate mofetil, daclizumab, and corticosteroids as mainstay immunosuppression in combination with low-dose cyclosporine, tacrolimus, or sirolimus, and compare it to that of renal transplant recipients receiving standard immunosuppression with mycophenolate mofetil, normal dose cyclosporine and corticosteroids.


Options:
A: Arm Label: Everolimus + Low dose CsA +PD; Type: EXPERIMENTAL; Interventions: Drug: Everolimus + Low dose CsA +PD | Arm Label: Myfortic+ Standard CsA + PD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Myfortic+ Standard CsA + PD | Intervention Type: DRUG; Name: Everolimus + Low dose CsA +PD; Assigned to Arm(s): Everolimus + Low dose CsA +PD | Intervention Type: DRUG; Name: Myfortic+ Standard CsA + PD; Assigned to Arm(s): Myfortic+ Standard CsA + PD
B: Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Intervention Type: DRUG; Name: AUC monitored withdrawal of MMF or CNI; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Safety and Efficacy of MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Combination With Low-Dose CsA, Tac or Sir in Comparison to Current Standard Immunosuppression (MMF, CsA and Corticosteroids) in Renal Tx
Brief Summary: To determine the renal function, as expressed by the glomerular filtration rate at 12 months, in renal transplant recipients receiving mycophenolate mofetil, daclizumab, and corticosteroids as mainstay immunosuppression in combination with low-dose cyclosporine, tacrolimus, or sirolimus, and compare it to that of renal transplant recipients receiving standard immunosuppression with mycophenolate mofetil, normal dose cyclosporine and corticosteroids.


Options:
A: Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): N/A
B: Arm Label: Basiliximab; Type: EXPERIMENTAL; Interventions: Drug: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) | Arm Label: Basiliximab-free; Type: ACTIVE_COMPARATOR; Interventions: Drug: MMF, cyclosporine, steroids | Intervention Type: DRUG; Name: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent); Assigned to Arm(s): Basiliximab | Intervention Type: DRUG; Name: MMF, cyclosporine, steroids; Assigned to Arm(s): Basiliximab-free
C: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
D: Arm Label: 1 Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simulect (basliximab) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Thymoglobulin [Anti-thymocyte Globulin (rabbit)] | Intervention Type: BIOLOGICAL; Name: Thymoglobulin [Anti-thymocyte Globulin (rabbit)]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Simulect (basliximab); Assigned to Arm(s): 1 Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With HIV Neuropathy.
Brief Summary: Study to determine if pregabalin is more effective than placebo in treating subjects with nerve pain associated with HIV neuropathy.


Options:
A: Arm Label: 1: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1: Pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2: Placebo
B: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matched placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure
Brief Summary: In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack. However, it is not known how patients with established mild-to-moderate heart failure (NYHA Class II), who have the additional risk of sudden death, will respond if treated with eplerenone. In this trial, eplerenone plus standard heart failure medicines is being compared to placebo plus standard heart failure medicines in terms of an additional ability to prolong life and prevent re-hospitalizations for worsening heart failure in these patients.

The Data Safety Monitoring Committee (DSMC) observed during its conduct of the protocol-specified second interim analysis on the 6th of May, 2010 that the efficacy of eplerenone had met the pre-specified stopping rules in the protocol. As a result of the discussion between the DSMC and the Executive Steering Committee (ESC), the ESC recommended that EMPHASIS-HF should be terminated, Based on the convincing efficacy and the consideration that it would be unethical not to offer this treatment to patients, the ESC recommended that all the patients in the trial should be transferred to open-label eplerenone. The Open Label Extension eplerenone arm will last for 12 months. Eplerenone is not currently approved for the indication studied in this patient population.

On May 26, 2010, further enrollment into EMPHASIS-HF was stopped. The amendment is considered to be the most appropriate way to ensure that all the subjects who participated in the double-blind phase of the EMPHASIS-HF trial can be offered treatment with eplerenone


Options:
A: Arm Label: Eplerenone arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone arm
B: Arm Label: Ivabradine; Type: EXPERIMENTAL; Interventions: Drug: Ivabradine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivabradine; Assigned to Arm(s): Ivabradine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ivabradine | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ivabradine | Intervention Type: DRUG; Name: Ivabradine; Assigned to Arm(s): Active arm, Placebo arm
D: Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure
Brief Summary: In an earlier study, eplerenone was shown to improve survival in patients who had heart failure immediately following a heart attack. However, it is not known how patients with established mild-to-moderate heart failure (NYHA Class II), who have the additional risk of sudden death, will respond if treated with eplerenone. In this trial, eplerenone plus standard heart failure medicines is being compared to placebo plus standard heart failure medicines in terms of an additional ability to prolong life and prevent re-hospitalizations for worsening heart failure in these patients.

The Data Safety Monitoring Committee (DSMC) observed during its conduct of the protocol-specified second interim analysis on the 6th of May, 2010 that the efficacy of eplerenone had met the pre-specified stopping rules in the protocol. As a result of the discussion between the DSMC and the Executive Steering Committee (ESC), the ESC recommended that EMPHASIS-HF should be terminated, Based on the convincing efficacy and the consideration that it would be unethical not to offer this treatment to patients, the ESC recommended that all the patients in the trial should be transferred to open-label eplerenone. The Open Label Extension eplerenone arm will last for 12 months. Eplerenone is not currently approved for the indication studied in this patient population.

On May 26, 2010, further enrollment into EMPHASIS-HF was stopped. The amendment is considered to be the most appropriate way to ensure that all the subjects who participated in the double-blind phase of the EMPHASIS-HF trial can be offered treatment with eplerenone


Options:
A: Arm Label: Eplerenone arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone arm
B: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: losartan 100 mg orally once daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: spironolactone 25 mg orally once daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo once orally once daily; Assigned to Arm(s): N/A
D: Arm Label: addition of spironolactone; Type: EXPERIMENTAL; Interventions: Drug: spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): addition of spironolactone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to investigate whether fish oil supplements may reduce the frequency and duration of paroxysmal atrial fibrillation episodes.

Atrial fibrillation is a heart condition which effects a large percentage of the population .

Atrial fibrillation is a condition frequently experienced by people who have had pacemakers inserted .

Certain Pacemakers have sophisticated monitoring features that are able to recognise episodes of atrial fibrillation.

Fish oil supplements may be of benefit to patients with heart problems.Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

By interrogating pacemakers this study will investigate the effect of fish oil supplements on the frequency and duration of episodes of atrial fibrillation.


Options:
A: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group
B: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
C: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
D: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to investigate whether fish oil supplements may reduce the frequency and duration of paroxysmal atrial fibrillation episodes.

Atrial fibrillation is a heart condition which effects a large percentage of the population .

Atrial fibrillation is a condition frequently experienced by people who have had pacemakers inserted .

Certain Pacemakers have sophisticated monitoring features that are able to recognise episodes of atrial fibrillation.

Fish oil supplements may be of benefit to patients with heart problems.Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.

By interrogating pacemakers this study will investigate the effect of fish oil supplements on the frequency and duration of episodes of atrial fibrillation.


Options:
A: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
B: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
C: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
D: Arm Label: Vitamin D3 + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: fish oil | Arm Label: Vitamin D3 + fish oil placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: Fish oil placebo | Arm Label: Vitamin D3 placebo + fish oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: fish oil, Dietary Supplement: Vitamin D3 placebo | Arm Label: Vitamin D3 placebo + fish oil placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 placebo, Dietary Supplement: Fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 + fish oil, Vitamin D3 + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): Vitamin D3 + fish oil, Vitamin D3 placebo + fish oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 placebo; Assigned to Arm(s): Vitamin D3 placebo + fish oil, Vitamin D3 placebo + fish oil placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil placebo; Assigned to Arm(s): Vitamin D3 + fish oil placebo, Vitamin D3 placebo + fish oil placebo

Answer: B